In order for our site to display correctly you will need a newer version of your web browser.
The following browsers support numerous web standards including CSS,XHTML, and the DOM (a universal means of controlling the behavior of web pages):
- Netscape v7 or higher (all platforms), Mozilla FireFox (Windows), Camino (Mac OS X), Galeon (Linux GNOME Desktop) or other browser stemming from the Mozilla.org project.
- Opera v7 or higher (Windows, Linux)
- Apple's Safari (Mac OS X)
- Konqueror (Linux KDE Desktop)
- Microsoft Internet Explorer v6 or higher (Windows) or v5 or higher (Macintosh)
Please note that this is not intended be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
Finding Cures. Saving Children.
Leukemia / Lymphoma Program Featured Research
A list of recent featured research from the Leukemia / Lymphoma team.
St. Jude scientists identify a completely new and deadly subtype of leukemia that arises from early T-cell precursors. The discovery allows early detection and therapeutic intervention to improve the outcome for children with this form of drug-resistant leukemia.
Researchers identified a new chromosomal abnormality in acute lymphoblastic leukemia (ALL) that appears to work in concert with another mutation to give rise to cancer. This latest anomaly is particularly common in children with Down syndrome.
Scientists at St. Jude Children’s Research Hospital have identified inherited variations in two genes that account for 37 percent of childhood acute lymphoblastic leukemia (ALL), including a gene that may help predict drug response.
The most comprehensive analysis yet of the genome of childhood acute myeloid leukemia (AML) found only a few mistakes in the genetic blueprint, suggesting the cancer arises from just a handful of missteps, according to new findings from St. Jude Children’s Research Hospital.
Childhood acute lymphoblastic leukemia (ALL) can be successfully treated using a carefully personalized chemotherapy regimen without cranial radiation, investigators at St. Jude Children's Research Hospital have found. Such radiation of the brain was once a standard ALL treatment to prevent recurrence of the leukemia in the central nervous system (CNS).
A research team has pinpointed a new class of gene mutations, which identify cases of childhood acute lymphoblastic leukemia (ALL) that have a high risk of relapse and death.
Scientists at St. Jude Children’s Research Hospital who represent the interdisciplinary team studying acute lymphoblastic leukemia (ALL) have been recognized by the American Association for Cancer Research (AACR) with the AACR Team Science Award.
For the first time, St. Jude researchers have identified a subtype of acute T-lymphoblastic leukemia (T-ALL) that is resistant to standard chemotherapy. They are planning to use this new insight to diagnose the disease in children with the subtype and to use bone marrow transplants to more effectively treat the disease.
Scan of thousands of inherited genetic changes reveal specific variations linked to treatment failure and the fate of chemotherapy drugs in the body for children with acute lymphoblastic leukemia.
Scientists have identified genetic mutations that predict a high likelihood of relapse in children with acute lymphoblastic leukemia (ALL).
Scientists at St. Jude have identified distinctive genetic changes that cause relapse in children with acute lymphoblastic leukemia (ALL).
St. Jude investigators have found that a protein called Puma, which normally protects the body by triggering cancer cells to commit suicide through a process called apoptosis, is suppressed in Burkitt lymphoma.
The supportive care of children suffering from early complications of acute myeloid leukemia (AML) has greatly reduced their death rate, according to a new St. Jude study.
Clinicians have achieved a gratifyingly high success rate in treating childhood leukemias — a major challenge is to improve treatment of central nervous system (CNS) leukemia.
A gene called N-Myc leads a double life in certain white blood cells when it is overexpressed, helping to trigger a cancer called acute myeloid leukemia (AML) under some conditions while triggering apoptosis, or cell suicide, under other conditions, according to results of a study done by St. Jude investigators.
